← ACHIEVE LIFE SCIENCES, INC. (ACHV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ACHIEVE LIFE SCIENCES, INC. (ACHV)
In Vitro & In Vivo Diagnostic Substances · market cap $807M · as of 2026-07-07
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
11
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Achieve Life Sciences (ACHV) is a clinical-stage company whose lead asset is cytisinicline, a Phase 3 smoking cessation candidate. With ~$28M cash and roughly 12 months of runway, the company operates under meaningful near-term financing pressure. The pipeline also lists a broad array of oncology assets, but the smoking cessation program is the primary value driver cited by the 10-analyst consensus.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TOCOSOL Paclitaxel | Phase 2 | Bladder Neoplasms |
| S-8184 Paclitaxel Injectable Emulsion | Phase 2 | Urologic Neoplasms |
| Cytisinicline | Phase 3 | Smoking Cessation |
| Custirsen | Phase 3 | Prostate Cancer |
| custirsen (OGX-011)/mitoxantrone | Phase 2 | Prostate Cancer |
| custirsen sodium | Phase 3 | Non-small Cell Lung Cancer |
| Cytisine | Phase 2 | Smoking Cessation |
| cabazitaxel | Phase 3 | Prostate Cancer |
| OGX-427 600 mg | Phase 2 | Urologic Neoplasms |
| TOCOSOL(R) Paclitaxel | Phase 2 | Breast Cancer |
| OGX-427 | Phase 2 | Castration Resistant Prostate Cancer |
Price & technical context
3-month
+17.7%
6-month
+139.8%
12-month
+139.0%
52-wk range
$2.65–$8.53
vs 50-day MA
+1.5%
vs 200-day MA
+38.7%
Realized vol
87.8%
Max drawdown
-62.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ACHV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.